Author: ALLISON GATLIN
Source
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
The post Nuvalent Flies On ‘Multibillion-Dollar’ Potential, While Iteos Crashes On Patient Deaths appeared first on Investor’s Business Daily.